Skip to main content

Advertisement

SpringerLink
Log in

Combination Therapy of Transcatheter Arterial Chemoembolization and Arterial Administration of Antiangiogenesis on VX2 Liver Tumor

  • Laboratory Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

An Erratum to this article was published on 15 September 2011

Abstract

Purpose

This study was designed to evaluate the antitumorigenic efficiency of Endostar (an antiangiogenic agent) arterially administrated combined with transcatheter arterial chemoembolization (TACE) on liver tumor, and validation of perfusion CT for quantitative measurements of the results.

Experimental Design

Thirty rabbits bearing VX2 liver tumors were randomly and equally distributed into three groups. One of the following treatment protocols was performed in each group: 1) group 1 was treated with TACE and simultaneously arterially administrated Endostar; 2) group 2 with TACE alone, and 3) a control group that had saline injected through hepatic artery. Routine CT scan was performed before treatment, and perfusion CT imaging was performed 2 weeks after treatment. Immunohistochemical biomarkers of microvascular density (MVD) and the expression of vascular endothelial growth factor (VEGF) were measured for assessments of angiogenesis.

Results

We observed a statistically significant reduction from the control in the volume, growth rate, and size of the tumor 2 weeks after treatment with both TACE plus Endostar and with TACE alone (P < 0.01). Although there was no statistically significant difference in tumor size between the group with TACE plus Endostar and the group with TACE alone (P > 0.05), MVD and VEGF were significantly less expressed in the TACE plus Endostar group than both groups with TACE alone and the control group (P < 0.01). Blood flow (BF), blood volume (BV), and permeability-surface area products (PS) in the group with TACE plus Endostar on perfusion CT were significantly higher than other two groups (P < 0.05), which were positively correlated with the MVD and VEGF values (P < 0.05).

Conclusions

TACE with arterial administration of Endostar simultaneously significantly inhibited the angiogenesis biomarkers associated with TACE in a rabbit model bearing VX2 liver tumor, which indicates that the combined treatment protocol may have potential synergistic effects on liver cancer. It also is suggested that perfusion CT may be useful for monitoring antiangiogenic/antivascular treatment in the liver tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543

    Article  PubMed  CAS  Google Scholar 

  2. Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  3. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  4. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25

    Article  PubMed  Google Scholar 

  5. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D (2006) Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17:217–223

    Article  PubMed  Google Scholar 

  6. Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10:1885–1889

    PubMed  Google Scholar 

  7. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878–2882

    PubMed  CAS  Google Scholar 

  8. Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38:160–166

    Article  PubMed  CAS  Google Scholar 

  9. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z (2006) Effect of Transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516–521

    Article  PubMed  Google Scholar 

  10. Guo WJ, Li J, Chen Z et al (2004) Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion. Hepatogastroenterology 51:381–386

    PubMed  CAS  Google Scholar 

  11. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other disease. Nature 407:249–257

    Article  PubMed  CAS  Google Scholar 

  12. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333–346

    Article  PubMed  CAS  Google Scholar 

  13. Rhee TK, Young JY, Larson AC et al (2007) Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1α in rabbit VX2 liver tumors. JVIR 18:639–646

    Article  PubMed  Google Scholar 

  14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34

    Article  PubMed  CAS  Google Scholar 

  16. O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285

    Article  PubMed  Google Scholar 

  17. Graepler F, Verbeek B, Graeter T et al (2005) Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41:879–886

    Article  PubMed  CAS  Google Scholar 

  18. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594–607

    Article  PubMed  CAS  Google Scholar 

  19. Liu F, Tan G, Li J, Dong X, Krissansen GW, Sun X (2007) Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci 98:1381–1387

    Article  PubMed  CAS  Google Scholar 

  20. Wang J, Sun Y, Liu Y et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 8:283–290

    Article  Google Scholar 

  21. Ling Y, Yang Y, Lu N et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79–84

    Article  PubMed  CAS  Google Scholar 

  22. Kulke MH, Bergsland EK, Ryan DP et al (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555–3561

    Article  PubMed  CAS  Google Scholar 

  23. Weidner N (1995) Intratumor mocrovessel density as a prognostic factor in cancer. Am J Pathol 147:9–19

    PubMed  CAS  Google Scholar 

  24. Vermeulen PB, Gasparini G, Fox SB et al (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumors. Eur J Cancer 38:1564–1579

    Article  PubMed  CAS  Google Scholar 

  25. Fox SB (1997) Tumor angiogenesis and prognosis. Histopathology 30:294–301

    Article  PubMed  CAS  Google Scholar 

  26. Bellomi M, Viotti S, Preda L et al (2010) Perfusion CT in solid body-tumours. Part II: clinical applications and future development. Radiol Med 115(6):858–874

    Article  PubMed  CAS  Google Scholar 

  27. Avinash R et al (2009) Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 47:161–178

    Article  Google Scholar 

  28. Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology 243:736–743

    Article  PubMed  Google Scholar 

  29. Wu HP, Feng GS, Liang HM et al (2004) Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol 10:813–818

    PubMed  CAS  Google Scholar 

  30. Maataoui A, Qian J, Vossoughi D et al (2005) Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 15(1):127–133

    Article  PubMed  CAS  Google Scholar 

  31. Piguet AC, Semela D, Keogh A et al (2008) Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49(1):78–87

    Article  PubMed  CAS  Google Scholar 

  32. Kan ZX, Phongkitkarun S, Kobayashi S et al (2005) Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237:151–158

    Article  PubMed  Google Scholar 

  33. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosenitizatin strategy for cancer? Science 312:1171–1175

    Article  PubMed  CAS  Google Scholar 

  34. Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989

    Article  PubMed  CAS  Google Scholar 

  35. Poon RT, Ng IO, Lau C et al (2001) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235

    Article  PubMed  CAS  Google Scholar 

  36. Wintermark M, Thiran JP, Maeder P, Schnyder P, Meuli R (2001) Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. Am J Neuroradiol 22:905–914

    PubMed  CAS  Google Scholar 

  37. Hakimé A, Peddi H, Hines-Peralta AU et al (2007) CT perfusion for determination of pharmacologically mediated blood flow changes in an animal tumor model. Radiology 243:712–719

    Article  PubMed  Google Scholar 

  38. Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C (2005) Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology 237:144–150

    Article  PubMed  Google Scholar 

  39. Yoon CJ, Chung JW, Park JH et al (2003) Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229:126–131

    Article  PubMed  Google Scholar 

  40. Yoon CJ, Chung JW, Park JH et al (2004) Transcatheter arterial embolization with 188Rhenium-HDD-labeled iodized oil in rabbit VX2 liver tumor. J Vasc Interv Radiol 15:1121–1128

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Zuxing Kan, from M.D. Anderson Medical Center, for his revision and valuable comments. This project was sponsored by National Natural Science Foundation of China (NSFC#30870703, 30910103905).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Jiangsu Key Laboratory of Molecular Imaging and Function Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, 87# Dingjiaqiao Road, Nanjing, 210009, China

    Gang Deng, Deng-Ling Zhao, Guang-Chao Li, Hui Yu & Gao-Jun Teng

Authors
  1. Gang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deng-Ling Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang-Chao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gao-Jun Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gao-Jun Teng.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00270-011-0274-z

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deng, G., Zhao, DL., Li, GC. et al. Combination Therapy of Transcatheter Arterial Chemoembolization and Arterial Administration of Antiangiogenesis on VX2 Liver Tumor. Cardiovasc Intervent Radiol 34, 824–832 (2011). https://doi.org/10.1007/s00270-011-0179-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-011-0179-x

Keywords

Search

Navigation